{"ticker": {"uuid": "e1f91757-a5c4-4337-ad09-dbde96c2aa62", "symbol": "CTXR", "name": "Citius Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/citius-oncology-reports-nationwide-deployment-131700443.html", "source_name": "PR Newswire", "published_at": "2026-07-21T13:17:00+00:00", "published_display": "21 Jul 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Citius Oncology (CTOR) Registration filing Summary", "summary": "Citius Oncology (CTOR) focuses on developing targeted oncology therapies, with its lead product LYMPHIR, approved by the FDA in August 2024 and launched in December 2025. The company became public via a reverse merger in August 2024. Recent financial activities include offerings ", "url": "https://quartr.com/events/citius-oncology-inc-ctor-registration-filing_FTqHlKVe", "source_name": "Quartr", "published_at": "2026-07-16T03:41:31", "published_display": "16 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. \u2013 NASDAQ:CTXR", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPVFVlUldSVUZVME5PQTByRWl6dlRQX3EyR05wNVZOWUlrTHhJRHF3TVMxNTZPaEMyWlVueEx0ZEZEemJwZFYxbW83bDU3c0s1VDdJdUlnWllWcVZyY2hJQTY4VG53cUJsMU9wTEpOR2RkU2M4TzduM0xXQWw3OEwxbFloSnpLOV91OW1GSkIzRGFPNEpfbkJSM2JoWlJqX2lrWG4xenZnd2VLVmot?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T00:24:26+00:00", "published_display": "15 Jul 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of Citius Pharmaceuticals Inc \u2013 LS:A40MD0", "summary": "This article provides financial information for Citius Pharmaceuticals Inc (LS:A40MD0) on TradingView, specifically focusing on its enterprise value to revenue forward. It appears to be a stub or data-centric page within a larger financial platform, offering no descriptive text b", "url": "https://www.tradingview.com/symbols/LS-A40MD0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T10:41:01", "published_display": "11 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBrOTFtaVFUOWU3T2FIMW9LV3JUWGRSV05wb1JtTUNIZVo5ZkVvM3pWTzF3d19odGMxdnBfYkFETzFCUVljMlRIY2Z4UG8yem5nb1p0eHhnYUozMzQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:00:01+00:00", "published_display": "11 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals updates pipeline as investors track CTXR stock", "summary": "Citius Pharmaceuticals is advancing its specialty pharmaceutical pipeline, with its CTXR stock attracting investor attention due to its focus on critical care and oncology support. As a development-stage company, CTXR's valuation is highly sensitive to clinical progress, regulato", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/citius-pharmaceuticals-updates-pipeline-as-investors-track-ctxr-stock/69717289", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:12:59", "published_display": "07 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why", "summary": "Citius Pharmaceuticals Inc (CTXR) is highlighted as a biotech opportunity due to operational developments not yet reflected in its share price. The company has two main assets: Mino-Lok, a treatment for catheter-related blood stream infections, and Hydro-Lido, a pharmaceutical-gr", "url": "https://www.insiderfinancial.com/citius-pharmaceuticals-inc-otcmktsctxr-is-a-biotech-runner-heres-why/171728", "source_name": "Insider Financial", "published_at": "2026-07-02T23:40:00", "published_display": "02 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. \u2013 NASDAQ:CTXR", "summary": "This article provides financial data for Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data output from TradingView, displaying key financial metrics without further analysis or textua", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:21", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Citius Pharmaceuticals, Inc. \u2013 NASDAQ:CTXR", "summary": "This article displays the \"Price to earnings forward\" financial metric for Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) on TradingView. It presents financial overview information related to the company's stock performance. The content is primarily a listing within the TradingView ", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:10:37", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. \u2013 BOATS:CTXR", "summary": "This article focuses on the enterprise value to revenue forward for Citius Pharmaceuticals, Inc. (CTXR). It appears to be a financial snapshot or data point from TradingView, highlighting a specific metric for the company. The content shown is primarily navigational and introduct", "url": "https://www.tradingview.com/symbols/BOATS-CTXR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:37", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. \u2013 BOATS:CTXR", "summary": "The article provides a financial glance at Citius Pharmaceuticals, Inc. (CTXR) focusing on its Enterprise Value to EBIT forward metric. It appears to be a snapshot from a financial data platform like TradingView, indicating that the market was closed at the time of publication an", "url": "https://www.tradingview.com/symbols/BOATS-CTXR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:10", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR)", "summary": "This article provides an overview of Citius Pharmaceuticals Inc. (CTXR) stock performance, financial data, and analyst estimates. Key information includes its current stock price, recent price changes, analyst forecasts, historical highs and lows, market capitalization, upcoming ", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:10", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "47N0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Citius Pharmaceuticals Inc (47N0) stock, indicating a 1-year price target of 3.44 EUR from one analyst. It details the company's financial metrics, including past earnings and revenue, and key information like its next earnings date (August 17", "url": "https://www.tradingview.com/symbols/FWB-47N0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:13", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Citius Pharmaceuticals, Inc. \u2013 BOATS:CTXR", "summary": "The article displays the \"Price to sales forward\" metric for Citius Pharmaceuticals, Inc. (CTXR) within the TradingView platform. It provides a snapshot of the company's financial data under the \"Blue Ocean Alternative Trade System\" (BOATS) and indicates that the market is curren", "url": "https://www.tradingview.com/symbols/BOATS-CTXR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:41", "published_display": "25 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Citius Pharmaceuticals, Inc. (CTXR) stock for 2027 based on analyst opinions. It includes financial data, stock performance, market capitalization, earnings reports, and historical price information, highlighting a 1-year pric", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:13", "published_display": "25 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Citius Pharmaceuticals Inc (CTXR), highlighting its current earnings forecast score, average price target, and expected revenue and EPS for upcoming periods. It details analyst predictions for the stock's price, revenue, and earnings", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T17:41:00", "published_display": "18 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Citius Pharmaceuticals Inc (CTXR) shareholder structure, detailing major individual and institutional shareholders. It presents data on the proportion of shares held by various entities and shareholder types, along with historical institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:51", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Citius Pharmaceuticals Inc (CTXR) stock information, including its current dividend history and stock split data. The company has not distributed dividends in the past five years, but it has several upcoming stock merger events scheduled for N", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:11", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Citius Pharmaceuticals Inc (CTXR)'s institutional confidence score and related shareholder activity. It details the shares held by various institutional investors and the percentage change in their holdings. The report highligh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T04:39:07", "published_display": "17 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Citius Pharmaceuticals Inc (CTXR), revealing a current financial score of 7.91, ranking 72 out of 388 in the Biotechnology & Medical Research industry. The company's financial status is described as weak, though its operating e", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T03:39:07", "published_display": "17 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Citius Pharmaceuticals Inc (CTXR), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 16, 2026, CTXR's price momentum score is 2.04, placing it low within it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/technical", "source_name": "TradingKey", "published_at": "2026-06-17T03:39:07", "published_display": "17 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (Nasdaq:CTXR) - Stock Analysis", "summary": "This article provides a stock analysis of Citius Pharmaceuticals (Nasdaq:CTXR), highlighting its current market capitalization, analyst price target indicating it's undervalued, and projected earnings growth. It also delves into various risks, including share price volatility, sh", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-06-04T11:40:11", "published_display": "04 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR - Citius Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for Citius Pharmaceuticals Inc (CTXR), including its current stock price, financial metrics, and recent news. It highlights the company's focus on critical care products, particularly in oncology and anti-infectives, and lists signi", "url": "https://finviz.com/stock?t=CTXR", "source_name": "Finviz", "published_at": "2026-06-03T23:40:00", "published_display": "03 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing", "summary": "This SEC filing for Citius Pharmaceuticals, Inc. (CTXR) is an \"EFFECT\" filing, indicating a Notice of Effectiveness for an S-3 form with an effective date of June 2, 2026, at 4:15 P.M. The filing detail includes the company's CIK and file number. The impact and sentiment of this ", "url": "https://www.stocktitan.net/sec-filings/CTXR/effect-citius-pharmaceuticals-inc-sec-filing-7609b5862852.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:10:34", "published_display": "03 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (CTXR) 10K Form and Latest SEC Filings 2026", "summary": "MarketBeat provides an overview of Citius Pharmaceuticals' (CTXR) SEC filings, including its 10K forms, 10Q reports, and 8K current reports. The article details how investors can use these publicly available documents to evaluate the company's financial health, with the most rece", "url": "https://www.marketbeat.com/stocks/NASDAQ/CTXR/sec-filings/", "source_name": "MarketBeat", "published_at": "2026-06-02T23:10:23", "published_display": "02 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data", "summary": "Citius Oncology (NASDAQ: CTXR) announced early Phase 1 data for LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. The study, involving 21 efficacy-evaluable patients, showed a 48% clinical benefit rate and a median prog", "url": "https://www.stocktitan.net/sec-filings/CTXR/8-k-citius-pharmaceuticals-inc-reports-material-event-2db1f228f767.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:40:18", "published_display": "01 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR\u00ae (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNTzFzTDh6NFhJQ3hiQ1N1bDE2X09pNUg2YjM4OEo3VVNab2haRkdUOV9TNnhfWGI4OFJCR3NKSmpaTkJnTHlaVU1JSWhiUFVLUWFRUThBTlVzSkhybzZza283ZXhXSU9Kbl80S1IwOEZRMTdVc25wN2VvSnA2ckJWaEhrcDc0VURKWkZmRTJObDFaT3o1T250TXk5ZlFFYlZPbHpzZ1ZNQ25nTGliVWdFaDhlZHZIYTFfbDQ2Q21vbjZURmVvRlN0Xw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)", "summary": "Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is projected to reach breakeven within just over a year, with analysts forecasting a final loss in 2026 before generating positive profits of US$27m in 2027. This profitability hinges on an average annual growth rate of 56%. The company,", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals/news/breakeven-on-the-horizon-for-citius-pharmaceuticals-inc-nasd", "source_name": "Simply Wall Street", "published_at": "2026-05-28T11:39:56", "published_display": "28 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Presentation of LYMPHIR\u00ae Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting \u2013 Company Announcement - FT.com", "summary": "Citius Oncology announced that data from an investigator-initiated Phase 1 study of LYMPHIR\u00ae in combination with pembrolizumab for relapsed/refractory gynecologic malignancies will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study sho", "url": "https://markets.ft.com/data/announce/detail?dockey=600-202605260800PR_NEWS_USPRX____NY67421-1", "source_name": "Financial Times", "published_at": "2026-05-26T11:40:33", "published_display": "26 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVDAxTDFILU9FYTZzaUhHQjJHUXhxMEFHeHowTzMtZWZ4QnJ3ZWZ0QnVtOHk4cnp1SzdwYzQzSnd1Z3dBWGpIUHNtV2xMSWxWWWdlTHRfa1Y2QW84Z3RzejJZbHluTUZhdWFmWlA2M2kwMmdtSVowZ19ubDZYZHRsV0ZhUnpEQVFRdklzVm1SU0lza1Y3RUllZ2trQUtoVGplUmZqcw?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants", "summary": "Citius Pharmaceuticals (NASDAQ: CTXR) has registered 5.43 million shares for resale, stemming from the potential exercise of common and placement agent warrants. While the company will not receive proceeds directly from these resales, it could gain up to $4.8 million if all warra", "url": "https://www.stocktitan.net/sec-filings/CTXR/s-3-citius-pharmaceuticals-inc-shelf-registration-statement-ce16a8da4725.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:38:59", "published_display": "22 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Rated Penny Stocks to Buy According to Wall Street Analysts", "summary": "This article highlights Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) as one of the top-rated penny stocks by Wall Street analysts. H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing encouraging early commercial launch metrics for the company's lead t", "url": "https://www.insidermonkey.com/blog/5-best-rated-penny-stocks-to-buy-according-to-wall-street-analysts-1764566/3/", "source_name": "Insider Monkey", "published_at": "2026-05-22T02:09:13", "published_display": "22 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Initiates Citius Pharmaceuticals(CTXR.US) With Buy Rating, Announces Target Price $4", "summary": "H.C. Wainwright has initiated coverage on Citius Pharmaceuticals (CTXR.US) with a 'Buy' rating. The firm also set a target price of $4 for the company's stock.", "url": "https://www.moomoo.com/news/post/70225811/hc-wainwright-initiates-citius-pharmaceuticals-ctxrus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-05-19T11:08:56", "published_display": "19 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR Assumes Buy Rating by HC Wainwright & Co. -- Price Target at $4.00", "summary": "HC Wainwright & Co. has initiated coverage on Citius Pharmaceuticals (CTXR) with a Buy rating and a $4.00 price target, suggesting significant upside from its current price of $0.5455. The company, focused on oncology and anti-infectives with its product LYMPHIR, has a GF Score\u2122 ", "url": "https://www.gurufocus.com/news/8866666/ctxr-assumes-buy-rating-by-hc-wainwright-co-price-target-at-400?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news", "source_name": "GuruFocus", "published_at": "2026-05-19T05:08:56", "published_display": "19 May 2026 05:08", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Price Target Announced at $4.00/Share by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has set a price target of $4.00 per share for Citius Pharmaceuticals (NASDAQ: CTXR). This target suggests a potential upside for the stock from its current trading levels. This announcement is likely to be of interest to investors tracking pharmaceutical secto", "url": "https://www.moomoo.com/news/post/70190667/citius-pharmaceuticals-price-target-announced-at-4-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-18T19:40:04", "published_display": "18 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdDVVYXRySHpab0tWbjYxN3lMblY4dUEwMUNrNV9xLTYyYnVaTXMySXZURnNIeEk3eDA2bEhleGg5UUpndzd1TEFtaEp2bm91THdsMmdSX2ZFcU5ITFc0V3lyaV8xcVVEeWtDN1UtMHYtYjMwQk4yZmdHMjFkQ0VYVzBOZDZoZ0hfNzBnQjJpWHFiTExCOVk5RGZCNGM4bDJ2VEVyOTZoM0E3NnRBd0lZekcxdGhrenh2azNRSTV6MzNGU084ZlVxTjh2TWdJNHotdGxrUFk1ZElVS29GZFhXUWlfRkFULUxvUHZqelVR?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNSkZxSnRrbFFPWThNUElQOHU2UTRpOWZyOWFQM0d1TGFaSHZ3ZUdsSVBXelJsMjdYRFFtTEZ0d3gtNnpMUXhlbDNZSEQ4ei1RV000VXNSN1FkM0E4dDdHNTRmRlJBS1otQ0gtaGdQTHpXUmVhdDUzaXZmVFRUMHQ2ajR1OUp4Tl95amI2YTJCSUZYQW5pdVRQR1RfZlVLd1ZweU9oNVZaM0JFekdxOUxrdm54MXV3UzZWMlgtbWN0dVg4djh5YnJLTURYWTlJNTFBS1ZWSklMdXVxZFBia3hNclUxX2M3MjhEMVRCMFFBckNwWHpRUGJ3?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Citius Oncology Ships First International Order of LYMPHIR\u2122 to Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUlIwM0t2WXdRZzMzTzJtbWZtcVd1ekp5dThaY0hqbHhqdi1ETi05Q0ViUE5SbUZLSE9zckpPZmNaZ1VHT2FUc25qb0NUUHp5WE1hOVBSLUNja3VNdU9mMHNtZmVmZGFudzRKMVFITHpqQkhrVW1ReERYcFNVc2xqMlA2aFZPYmU2Rnl6T3dFQ055aTZubG9zTW55QWw1TEV5YzR0N2x2eDVsTHh3RWo3TURTSWEwWjROM2pfNVZKX2wzdw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citius-pharmaceuticals-announces-closing-registered-203000332.html", "source_name": "PR Newswire", "published_at": "2026-04-24T20:30:00+00:00", "published_display": "24 Apr 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Secures $5M Through Equity Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYmRIZzVCSkxJamVUYjRjNzlScXZzdzBCREFUdlJ4aDl2eGJqaTZ5THp4blJxSTYtOWNZaDJGMWx2ZTVJSkFkUGpCdUNEd2stSlRXa3lhTUw2bWFkSnZwRy1yNWNSaWxFVHh5UFdocWJKZ2JIaGJGTlo0ZW9xX1hZaVRNRHU0bm9LTjlsUWlsM1NZWU5OWE1nVzdmaE0wbmNId3c3RkhBeXk?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQV1pQZHM1VUN3M0p2VHltWlE2QWZoQjd1cUNObWc1QjlFNURRUWc4MmJwZnRxd0JjUzRJbDMxT0pqdjY5VmprSkxVeXRxWW9QdU4zLVE1U0RVbzM1ZVV5dXNMbkgxOVRNTzdsS1N6QUlybEQxVUxMU1E0a0VNUzdubUxYamhlZGdzMkpZai1TZTZ0Wm4wbGJyTHNpUXhkY3pUVU52Tmk1WEd1NEpfem84eEd3TjU4NmpKWnNFcE13T3FrTmZ0VWJzVjZLOUlDNzhUY2dsZ3loeGYwWUNUaktqSnVGQnd4ejVXc184NjhMUUh2a2xBbHdhQXdURUFQbEE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals closes $5M stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOajlkMzRsVllXcXdmRW5LZnd2Yk44RXJHWlpDQjhjSmcwMXAza25UaEF0Z2xJMXFpcTRHUWpsUnJGZFB2WGxPeWp3VDBzVGpYUWZUS1BMNWtGaExXcXVjYW1MRTdtLTg1Y3RfQjljcmJoU2ZDRnhIdFJ5LUowUGZDRlJEbTh3TzRZckF5S1pOcFpjbGF3dC1QUFN3dE0tMGw3bHBGRHFaTQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOazRFUmV3ZVNnMm5OaWVHNldVTVhLRmk0NXcxeHFycTY0TGM5Nk1sSTNwWXZESXhjMjctT0ZwdG5EU1dFZlAyXzVudXdFaTdKWDdGTWRmTHJwczhFOV9qemdUYmNmRi1YUDJlTXZXR3VScmhhS1duRnpiNVV5cUl0MDFuSXhNWEdDWWd5cnlXdXdHVjdQd25PMGNJOHhYMDB1U1NPckhybw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNMVZUMklzWWxqcHE3X2VYN0MzRWhabjY0MmpTbzVOSi1RbFV1Z2JIRU1NNklkMThrbDJ2NXFOOGkyZkJNYjk3RWV1ZUhCNV9XUUFhVnViMmFxQ09MZWsyRm1JZmhpZFIzLVZqMEJiUnR0c1Bka1NSZ0hTV3RFZVJpU1RjdXZNazhGc1ZtX25maVVCQXloQXZnS1Zjb2cxcmlRcHhBdFR1cTM1bFp1amFrWjlnN1FqU0k1cDJ1SkJxbFpqelFZX3ZGOFdMVjd3NHA4VmNWS3ViR2p2cUxSYzRF?oc=5", "source_name": "GuruFocus", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPMVNSWk9QT0RGRE5kbmptRWJOZDdEazFEWDVYTTNJazFZRlRrUVJaamxZX01QWTRtTGpvU3NsUE1ldThiVll0U1hub05QQ1hDTUt2U2NIQ1dUd20zUlBDazkwcEJfSEhnSFZyU214em03MVhSWFhVMTJMbElsZktUVXEydU5yUzA?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR\u2122", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxONDgxU3ZwZTE0VkQtSEQxdFhPTERjZGVhcldVVzl1ZG1yVWhWRUNQT3J5S3NFUmc5SWhlcmtBdkxyeEVla3diaFI0bl9Lcm5QTHhLYThwb0FoRlFCRllxOHdyYi0wZ1o2LUlLaXhBMVZ3ZWczUkRJeFUwcEk0T3FYOG5laWZtMEp3MlozOXprV2t6YzE1Um82cGszNEtlRDFKd0djdmFZQ1ZIZzMzbjlvMXFvWjFHRkw5RFFYRjd2dDV3ZGUyMGxTcFlnbl80QTFHWUFJVFVXSW5mRHVjOUNDaA?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Expands International Distribution of LYMPHIR\u2122 to European Union Through Exclusive Agreement with Uniphar", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNSEFyMnp6dmZvU2VTQ3N6SWRBM0Q5VDBlMUp6dWhrOUJzNVJfMzNMZFZ5QVZOU3Z1TnFNRlhEcXZ5bUdMZVNrd3lQMjc5eS1rZ2dFTjAwVUVEVU1EbTI1dmMxcVZvdjlCUFdUazFDZWNUUDdTTVVrM1pGTlVDcEFSelZ0TTlERnZld2tvelBtb1NHbFdMbjh2TWhTU0ZqRU04MFc4WW1pckFZcXZXVlhrTlBkclZXMW4xSVRoM2cza3ppYnB4eTJjQXBFWVN5eWlETTd4VFhGeGE4MTdoTHJfM1Q4WVhZT1lEMmNyTGFnUHVjNEF1emQ1M0l0NWVKeWsyT1RYSlBsVQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQcjF5V3RxZmVjbEdtWjBvenlUejNLeElVcXFVeUNmQUZVVDRmaEFZMVlXajhKbks0VEhWTlZNWk9xOE11a3VabXJiWXAtVXBWTENHZmtySFZJT3Y5eUVKM2VCLTFyMV81QWxiLXI1cFVqeTFnMTFrSFdMOFFjMnJMQ2wwNGl2U2x4dmxSd01MNzJRS2E5MnVQeEVsM1BBUDFWOWtKQk9xU0Z2aXdsVWU2X1RiSDVtcG0yb2Y1Q0lCV0NUbE5QdjJkU3RHMnBabzRQcm5DMkVldWRyMTh3eHFraDdIaw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZFdyamNvNXBRMk1paS1RT1RBNzJ4amZrSHM0OF9ZYXlycV9GZ201REdBQmRQWFEyVERjVmIzUFd5XzlrWVMyYU1TVllvajFkdGtPRzdXM2VWLTRTWGZoSVVlSFlRQTdqWFFucTZTWksxUjZNODdMRjdua3VQcEdSaVBicGdUVnpHbnlXamZER1VVckRWUTZvV0J0cDNkeXdkU3hfVW5WcnhLSUIzM3RNTVNxWFhWVVpzUUlnQ2xFWVZ6bGpfZEVvNFJ6TlUzcXFWQzBaeFZVQTV5VGFUOThBeU1EMUtScjVEMHc?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxPcnFyT1VfWTNhamdiWWktR2lKMWJWOXVucmJSaGMzUFp3ZzZtWDhFaTBvRWczSWY5QWxSX2dSQWJwSXVKdm04SkNVbnlmZDZUdkhEZjNuNl9VNVdyRHU1b01lLW9XWG4tVXpCejNybkRhaHZTc2JHVk1nUjFreFdzdDRhRFNZcFFCZFB6UXI5dFV5RFZfVDhjR2tNSWdwengzMVd1T0NCdXcyMFFKcUVNVk1RclM2RXNRdnpQQ0RsUlY5bWZyREhKQkc5cWJLYWV1MXpEV3Aza1BSaGRLWFNpT3BMaDBuY3lnRGoyR0cxTkluNWJGSElibW01S3Jvbjl2WENrY0plVTBvVlZrbE1rWnZ0UHk0X21kamJvRQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/citius-oncology-reports-nationwide-deployment-131700443.html", "source_name": "PR Newswire", "published_at": "2026-07-21T13:17:00+00:00", "published_display": "21 Jul 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) Registration filing Summary", "summary": "Citius Oncology (CTOR) focuses on developing targeted oncology therapies, with its lead product LYMPHIR, approved by the FDA in August 2024 and launched in December 2025. The company became public via a reverse merger in August 2024. Recent financial activities include offerings ", "url": "https://quartr.com/events/citius-oncology-inc-ctor-registration-filing_FTqHlKVe", "source_name": "Quartr", "published_at": "2026-07-16T03:41:31", "published_display": "16 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. \u2013 NASDAQ:CTXR", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPVFVlUldSVUZVME5PQTByRWl6dlRQX3EyR05wNVZOWUlrTHhJRHF3TVMxNTZPaEMyWlVueEx0ZEZEemJwZFYxbW83bDU3c0s1VDdJdUlnWllWcVZyY2hJQTY4VG53cUJsMU9wTEpOR2RkU2M4TzduM0xXQWw3OEwxbFloSnpLOV91OW1GSkIzRGFPNEpfbkJSM2JoWlJqX2lrWG4xenZnd2VLVmot?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T00:24:26+00:00", "published_display": "15 Jul 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Citius Pharmaceuticals Inc \u2013 LS:A40MD0", "summary": "This article provides financial information for Citius Pharmaceuticals Inc (LS:A40MD0) on TradingView, specifically focusing on its enterprise value to revenue forward. It appears to be a stub or data-centric page within a larger financial platform, offering no descriptive text b", "url": "https://www.tradingview.com/symbols/LS-A40MD0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T10:41:01", "published_display": "11 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBrOTFtaVFUOWU3T2FIMW9LV3JUWGRSV05wb1JtTUNIZVo5ZkVvM3pWTzF3d19odGMxdnBfYkFETzFCUVljMlRIY2Z4UG8yem5nb1p0eHhnYUozMzQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:00:01+00:00", "published_display": "11 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals updates pipeline as investors track CTXR stock", "summary": "Citius Pharmaceuticals is advancing its specialty pharmaceutical pipeline, with its CTXR stock attracting investor attention due to its focus on critical care and oncology support. As a development-stage company, CTXR's valuation is highly sensitive to clinical progress, regulato", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/citius-pharmaceuticals-updates-pipeline-as-investors-track-ctxr-stock/69717289", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:12:59", "published_display": "07 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why", "summary": "Citius Pharmaceuticals Inc (CTXR) is highlighted as a biotech opportunity due to operational developments not yet reflected in its share price. The company has two main assets: Mino-Lok, a treatment for catheter-related blood stream infections, and Hydro-Lido, a pharmaceutical-gr", "url": "https://www.insiderfinancial.com/citius-pharmaceuticals-inc-otcmktsctxr-is-a-biotech-runner-heres-why/171728", "source_name": "Insider Financial", "published_at": "2026-07-02T23:40:00", "published_display": "02 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. \u2013 NASDAQ:CTXR", "summary": "This article provides financial data for Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data output from TradingView, displaying key financial metrics without further analysis or textua", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:21", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Citius Pharmaceuticals, Inc. \u2013 NASDAQ:CTXR", "summary": "This article displays the \"Price to earnings forward\" financial metric for Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) on TradingView. It presents financial overview information related to the company's stock performance. The content is primarily a listing within the TradingView ", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:10:37", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. \u2013 BOATS:CTXR", "summary": "This article focuses on the enterprise value to revenue forward for Citius Pharmaceuticals, Inc. (CTXR). It appears to be a financial snapshot or data point from TradingView, highlighting a specific metric for the company. The content shown is primarily navigational and introduct", "url": "https://www.tradingview.com/symbols/BOATS-CTXR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:37", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. \u2013 BOATS:CTXR", "summary": "The article provides a financial glance at Citius Pharmaceuticals, Inc. (CTXR) focusing on its Enterprise Value to EBIT forward metric. It appears to be a snapshot from a financial data platform like TradingView, indicating that the market was closed at the time of publication an", "url": "https://www.tradingview.com/symbols/BOATS-CTXR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:10", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR)", "summary": "This article provides an overview of Citius Pharmaceuticals Inc. (CTXR) stock performance, financial data, and analyst estimates. Key information includes its current stock price, recent price changes, analyst forecasts, historical highs and lows, market capitalization, upcoming ", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:10", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "47N0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Citius Pharmaceuticals Inc (47N0) stock, indicating a 1-year price target of 3.44 EUR from one analyst. It details the company's financial metrics, including past earnings and revenue, and key information like its next earnings date (August 17", "url": "https://www.tradingview.com/symbols/FWB-47N0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:13", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Citius Pharmaceuticals, Inc. \u2013 BOATS:CTXR", "summary": "The article displays the \"Price to sales forward\" metric for Citius Pharmaceuticals, Inc. (CTXR) within the TradingView platform. It provides a snapshot of the company's financial data under the \"Blue Ocean Alternative Trade System\" (BOATS) and indicates that the market is curren", "url": "https://www.tradingview.com/symbols/BOATS-CTXR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:41", "published_display": "25 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Citius Pharmaceuticals, Inc. (CTXR) stock for 2027 based on analyst opinions. It includes financial data, stock performance, market capitalization, earnings reports, and historical price information, highlighting a 1-year pric", "url": "https://www.tradingview.com/symbols/NASDAQ-CTXR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:13", "published_display": "25 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Citius Pharmaceuticals Inc (CTXR), highlighting its current earnings forecast score, average price target, and expected revenue and EPS for upcoming periods. It details analyst predictions for the stock's price, revenue, and earnings", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T17:41:00", "published_display": "18 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Citius Pharmaceuticals Inc (CTXR) shareholder structure, detailing major individual and institutional shareholders. It presents data on the proportion of shares held by various entities and shareholder types, along with historical institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:51", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Citius Pharmaceuticals Inc (CTXR) stock information, including its current dividend history and stock split data. The company has not distributed dividends in the past five years, but it has several upcoming stock merger events scheduled for N", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:11", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Citius Pharmaceuticals Inc (CTXR)'s institutional confidence score and related shareholder activity. It details the shares held by various institutional investors and the percentage change in their holdings. The report highligh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T04:39:07", "published_display": "17 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Citius Pharmaceuticals Inc (CTXR), revealing a current financial score of 7.91, ranking 72 out of 388 in the Biotechnology & Medical Research industry. The company's financial status is described as weak, though its operating e", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T03:39:07", "published_display": "17 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Citius Pharmaceuticals Inc (CTXR), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 16, 2026, CTXR's price momentum score is 2.04, placing it low within it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctxr/technical", "source_name": "TradingKey", "published_at": "2026-06-17T03:39:07", "published_display": "17 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (Nasdaq:CTXR) - Stock Analysis", "summary": "This article provides a stock analysis of Citius Pharmaceuticals (Nasdaq:CTXR), highlighting its current market capitalization, analyst price target indicating it's undervalued, and projected earnings growth. It also delves into various risks, including share price volatility, sh", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-06-04T11:40:11", "published_display": "04 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR - Citius Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for Citius Pharmaceuticals Inc (CTXR), including its current stock price, financial metrics, and recent news. It highlights the company's focus on critical care products, particularly in oncology and anti-infectives, and lists signi", "url": "https://finviz.com/stock?t=CTXR", "source_name": "Finviz", "published_at": "2026-06-03T23:40:00", "published_display": "03 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing", "summary": "This SEC filing for Citius Pharmaceuticals, Inc. (CTXR) is an \"EFFECT\" filing, indicating a Notice of Effectiveness for an S-3 form with an effective date of June 2, 2026, at 4:15 P.M. The filing detail includes the company's CIK and file number. The impact and sentiment of this ", "url": "https://www.stocktitan.net/sec-filings/CTXR/effect-citius-pharmaceuticals-inc-sec-filing-7609b5862852.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:10:34", "published_display": "03 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (CTXR) 10K Form and Latest SEC Filings 2026", "summary": "MarketBeat provides an overview of Citius Pharmaceuticals' (CTXR) SEC filings, including its 10K forms, 10Q reports, and 8K current reports. The article details how investors can use these publicly available documents to evaluate the company's financial health, with the most rece", "url": "https://www.marketbeat.com/stocks/NASDAQ/CTXR/sec-filings/", "source_name": "MarketBeat", "published_at": "2026-06-02T23:10:23", "published_display": "02 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data", "summary": "Citius Oncology (NASDAQ: CTXR) announced early Phase 1 data for LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. The study, involving 21 efficacy-evaluable patients, showed a 48% clinical benefit rate and a median prog", "url": "https://www.stocktitan.net/sec-filings/CTXR/8-k-citius-pharmaceuticals-inc-reports-material-event-2db1f228f767.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:40:18", "published_display": "01 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR\u00ae (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNTzFzTDh6NFhJQ3hiQ1N1bDE2X09pNUg2YjM4OEo3VVNab2haRkdUOV9TNnhfWGI4OFJCR3NKSmpaTkJnTHlaVU1JSWhiUFVLUWFRUThBTlVzSkhybzZza283ZXhXSU9Kbl80S1IwOEZRMTdVc25wN2VvSnA2ckJWaEhrcDc0VURKWkZmRTJObDFaT3o1T250TXk5ZlFFYlZPbHpzZ1ZNQ25nTGliVWdFaDhlZHZIYTFfbDQ2Q21vbjZURmVvRlN0Xw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)", "summary": "Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is projected to reach breakeven within just over a year, with analysts forecasting a final loss in 2026 before generating positive profits of US$27m in 2027. This profitability hinges on an average annual growth rate of 56%. The company,", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals/news/breakeven-on-the-horizon-for-citius-pharmaceuticals-inc-nasd", "source_name": "Simply Wall Street", "published_at": "2026-05-28T11:39:56", "published_display": "28 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Presentation of LYMPHIR\u00ae Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting \u2013 Company Announcement - FT.com", "summary": "Citius Oncology announced that data from an investigator-initiated Phase 1 study of LYMPHIR\u00ae in combination with pembrolizumab for relapsed/refractory gynecologic malignancies will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study sho", "url": "https://markets.ft.com/data/announce/detail?dockey=600-202605260800PR_NEWS_USPRX____NY67421-1", "source_name": "Financial Times", "published_at": "2026-05-26T11:40:33", "published_display": "26 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVDAxTDFILU9FYTZzaUhHQjJHUXhxMEFHeHowTzMtZWZ4QnJ3ZWZ0QnVtOHk4cnp1SzdwYzQzSnd1Z3dBWGpIUHNtV2xMSWxWWWdlTHRfa1Y2QW84Z3RzejJZbHluTUZhdWFmWlA2M2kwMmdtSVowZ19ubDZYZHRsV0ZhUnpEQVFRdklzVm1SU0lza1Y3RUllZ2trQUtoVGplUmZqcw?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants", "summary": "Citius Pharmaceuticals (NASDAQ: CTXR) has registered 5.43 million shares for resale, stemming from the potential exercise of common and placement agent warrants. While the company will not receive proceeds directly from these resales, it could gain up to $4.8 million if all warra", "url": "https://www.stocktitan.net/sec-filings/CTXR/s-3-citius-pharmaceuticals-inc-shelf-registration-statement-ce16a8da4725.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:38:59", "published_display": "22 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Rated Penny Stocks to Buy According to Wall Street Analysts", "summary": "This article highlights Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) as one of the top-rated penny stocks by Wall Street analysts. H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing encouraging early commercial launch metrics for the company's lead t", "url": "https://www.insidermonkey.com/blog/5-best-rated-penny-stocks-to-buy-according-to-wall-street-analysts-1764566/3/", "source_name": "Insider Monkey", "published_at": "2026-05-22T02:09:13", "published_display": "22 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Initiates Citius Pharmaceuticals(CTXR.US) With Buy Rating, Announces Target Price $4", "summary": "H.C. Wainwright has initiated coverage on Citius Pharmaceuticals (CTXR.US) with a 'Buy' rating. The firm also set a target price of $4 for the company's stock.", "url": "https://www.moomoo.com/news/post/70225811/hc-wainwright-initiates-citius-pharmaceuticals-ctxrus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-05-19T11:08:56", "published_display": "19 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR Assumes Buy Rating by HC Wainwright & Co. -- Price Target at $4.00", "summary": "HC Wainwright & Co. has initiated coverage on Citius Pharmaceuticals (CTXR) with a Buy rating and a $4.00 price target, suggesting significant upside from its current price of $0.5455. The company, focused on oncology and anti-infectives with its product LYMPHIR, has a GF Score\u2122 ", "url": "https://www.gurufocus.com/news/8866666/ctxr-assumes-buy-rating-by-hc-wainwright-co-price-target-at-400?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news", "source_name": "GuruFocus", "published_at": "2026-05-19T05:08:56", "published_display": "19 May 2026 05:08", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Price Target Announced at $4.00/Share by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has set a price target of $4.00 per share for Citius Pharmaceuticals (NASDAQ: CTXR). This target suggests a potential upside for the stock from its current trading levels. This announcement is likely to be of interest to investors tracking pharmaceutical secto", "url": "https://www.moomoo.com/news/post/70190667/citius-pharmaceuticals-price-target-announced-at-4-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-18T19:40:04", "published_display": "18 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdDVVYXRySHpab0tWbjYxN3lMblY4dUEwMUNrNV9xLTYyYnVaTXMySXZURnNIeEk3eDA2bEhleGg5UUpndzd1TEFtaEp2bm91THdsMmdSX2ZFcU5ITFc0V3lyaV8xcVVEeWtDN1UtMHYtYjMwQk4yZmdHMjFkQ0VYVzBOZDZoZ0hfNzBnQjJpWHFiTExCOVk5RGZCNGM4bDJ2VEVyOTZoM0E3NnRBd0lZekcxdGhrenh2azNRSTV6MzNGU084ZlVxTjh2TWdJNHotdGxrUFk1ZElVS29GZFhXUWlfRkFULUxvUHZqelVR?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNSkZxSnRrbFFPWThNUElQOHU2UTRpOWZyOWFQM0d1TGFaSHZ3ZUdsSVBXelJsMjdYRFFtTEZ0d3gtNnpMUXhlbDNZSEQ4ei1RV000VXNSN1FkM0E4dDdHNTRmRlJBS1otQ0gtaGdQTHpXUmVhdDUzaXZmVFRUMHQ2ajR1OUp4Tl95amI2YTJCSUZYQW5pdVRQR1RfZlVLd1ZweU9oNVZaM0JFekdxOUxrdm54MXV3UzZWMlgtbWN0dVg4djh5YnJLTURYWTlJNTFBS1ZWSklMdXVxZFBia3hNclUxX2M3MjhEMVRCMFFBckNwWHpRUGJ3?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Ships First International Order of LYMPHIR\u2122 to Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUlIwM0t2WXdRZzMzTzJtbWZtcVd1ekp5dThaY0hqbHhqdi1ETi05Q0ViUE5SbUZLSE9zckpPZmNaZ1VHT2FUc25qb0NUUHp5WE1hOVBSLUNja3VNdU9mMHNtZmVmZGFudzRKMVFITHpqQkhrVW1ReERYcFNVc2xqMlA2aFZPYmU2Rnl6T3dFQ055aTZubG9zTW55QWw1TEV5YzR0N2x2eDVsTHh3RWo3TURTSWEwWjROM2pfNVZKX2wzdw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citius-pharmaceuticals-announces-closing-registered-203000332.html", "source_name": "PR Newswire", "published_at": "2026-04-24T20:30:00+00:00", "published_display": "24 Apr 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Secures $5M Through Equity Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYmRIZzVCSkxJamVUYjRjNzlScXZzdzBCREFUdlJ4aDl2eGJqaTZ5THp4blJxSTYtOWNZaDJGMWx2ZTVJSkFkUGpCdUNEd2stSlRXa3lhTUw2bWFkSnZwRy1yNWNSaWxFVHh5UFdocWJKZ2JIaGJGTlo0ZW9xX1hZaVRNRHU0bm9LTjlsUWlsM1NZWU5OWE1nVzdmaE0wbmNId3c3RkhBeXk?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQV1pQZHM1VUN3M0p2VHltWlE2QWZoQjd1cUNObWc1QjlFNURRUWc4MmJwZnRxd0JjUzRJbDMxT0pqdjY5VmprSkxVeXRxWW9QdU4zLVE1U0RVbzM1ZVV5dXNMbkgxOVRNTzdsS1N6QUlybEQxVUxMU1E0a0VNUzdubUxYamhlZGdzMkpZai1TZTZ0Wm4wbGJyTHNpUXhkY3pUVU52Tmk1WEd1NEpfem84eEd3TjU4NmpKWnNFcE13T3FrTmZ0VWJzVjZLOUlDNzhUY2dsZ3loeGYwWUNUaktqSnVGQnd4ejVXc184NjhMUUh2a2xBbHdhQXdURUFQbEE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals closes $5M stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOajlkMzRsVllXcXdmRW5LZnd2Yk44RXJHWlpDQjhjSmcwMXAza25UaEF0Z2xJMXFpcTRHUWpsUnJGZFB2WGxPeWp3VDBzVGpYUWZUS1BMNWtGaExXcXVjYW1MRTdtLTg1Y3RfQjljcmJoU2ZDRnhIdFJ5LUowUGZDRlJEbTh3TzRZckF5S1pOcFpjbGF3dC1QUFN3dE0tMGw3bHBGRHFaTQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOazRFUmV3ZVNnMm5OaWVHNldVTVhLRmk0NXcxeHFycTY0TGM5Nk1sSTNwWXZESXhjMjctT0ZwdG5EU1dFZlAyXzVudXdFaTdKWDdGTWRmTHJwczhFOV9qemdUYmNmRi1YUDJlTXZXR3VScmhhS1duRnpiNVV5cUl0MDFuSXhNWEdDWWd5cnlXdXdHVjdQd25PMGNJOHhYMDB1U1NPckhybw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNMVZUMklzWWxqcHE3X2VYN0MzRWhabjY0MmpTbzVOSi1RbFV1Z2JIRU1NNklkMThrbDJ2NXFOOGkyZkJNYjk3RWV1ZUhCNV9XUUFhVnViMmFxQ09MZWsyRm1JZmhpZFIzLVZqMEJiUnR0c1Bka1NSZ0hTV3RFZVJpU1RjdXZNazhGc1ZtX25maVVCQXloQXZnS1Zjb2cxcmlRcHhBdFR1cTM1bFp1amFrWjlnN1FqU0k1cDJ1SkJxbFpqelFZX3ZGOFdMVjd3NHA4VmNWS3ViR2p2cUxSYzRF?oc=5", "source_name": "GuruFocus", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPMVNSWk9QT0RGRE5kbmptRWJOZDdEazFEWDVYTTNJazFZRlRrUVJaamxZX01QWTRtTGpvU3NsUE1ldThiVll0U1hub05QQ1hDTUt2U2NIQ1dUd20zUlBDazkwcEJfSEhnSFZyU214em03MVhSWFhVMTJMbElsZktUVXEydU5yUzA?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR\u2122", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxONDgxU3ZwZTE0VkQtSEQxdFhPTERjZGVhcldVVzl1ZG1yVWhWRUNQT3J5S3NFUmc5SWhlcmtBdkxyeEVla3diaFI0bl9Lcm5QTHhLYThwb0FoRlFCRllxOHdyYi0wZ1o2LUlLaXhBMVZ3ZWczUkRJeFUwcEk0T3FYOG5laWZtMEp3MlozOXprV2t6YzE1Um82cGszNEtlRDFKd0djdmFZQ1ZIZzMzbjlvMXFvWjFHRkw5RFFYRjd2dDV3ZGUyMGxTcFlnbl80QTFHWUFJVFVXSW5mRHVjOUNDaA?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Expands International Distribution of LYMPHIR\u2122 to European Union Through Exclusive Agreement with Uniphar", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNSEFyMnp6dmZvU2VTQ3N6SWRBM0Q5VDBlMUp6dWhrOUJzNVJfMzNMZFZ5QVZOU3Z1TnFNRlhEcXZ5bUdMZVNrd3lQMjc5eS1rZ2dFTjAwVUVEVU1EbTI1dmMxcVZvdjlCUFdUazFDZWNUUDdTTVVrM1pGTlVDcEFSelZ0TTlERnZld2tvelBtb1NHbFdMbjh2TWhTU0ZqRU04MFc4WW1pckFZcXZXVlhrTlBkclZXMW4xSVRoM2cza3ppYnB4eTJjQXBFWVN5eWlETTd4VFhGeGE4MTdoTHJfM1Q4WVhZT1lEMmNyTGFnUHVjNEF1emQ1M0l0NWVKeWsyT1RYSlBsVQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQcjF5V3RxZmVjbEdtWjBvenlUejNLeElVcXFVeUNmQUZVVDRmaEFZMVlXajhKbks0VEhWTlZNWk9xOE11a3VabXJiWXAtVXBWTENHZmtySFZJT3Y5eUVKM2VCLTFyMV81QWxiLXI1cFVqeTFnMTFrSFdMOFFjMnJMQ2wwNGl2U2x4dmxSd01MNzJRS2E5MnVQeEVsM1BBUDFWOWtKQk9xU0Z2aXdsVWU2X1RiSDVtcG0yb2Y1Q0lCV0NUbE5QdjJkU3RHMnBabzRQcm5DMkVldWRyMTh3eHFraDdIaw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZFdyamNvNXBRMk1paS1RT1RBNzJ4amZrSHM0OF9ZYXlycV9GZ201REdBQmRQWFEyVERjVmIzUFd5XzlrWVMyYU1TVllvajFkdGtPRzdXM2VWLTRTWGZoSVVlSFlRQTdqWFFucTZTWksxUjZNODdMRjdua3VQcEdSaVBicGdUVnpHbnlXamZER1VVckRWUTZvV0J0cDNkeXdkU3hfVW5WcnhLSUIzM3RNTVNxWFhWVVpzUUlnQ2xFWVZ6bGpfZEVvNFJ6TlUzcXFWQzBaeFZVQTV5VGFUOThBeU1EMUtScjVEMHc?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxPcnFyT1VfWTNhamdiWWktR2lKMWJWOXVucmJSaGMzUFp3ZzZtWDhFaTBvRWczSWY5QWxSX2dSQWJwSXVKdm04SkNVbnlmZDZUdkhEZjNuNl9VNVdyRHU1b01lLW9XWG4tVXpCejNybkRhaHZTc2JHVk1nUjFreFdzdDRhRFNZcFFCZFB6UXI5dFV5RFZfVDhjR2tNSWdwengzMVd1T0NCdXcyMFFKcUVNVk1RclM2RXNRdnpQQ0RsUlY5bWZyREhKQkc5cWJLYWV1MXpEV3Aza1BSaGRLWFNpT3BMaDBuY3lnRGoyR0cxTkluNWJGSElibW01S3Jvbjl2WENrY0plVTBvVlZrbE1rWnZ0UHk0X21kamJvRQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 68, "sentiment_summary": {"positive": 15, "negative": 4, "neutral": 49, "score": 54, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}], "positive_events": 15, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 0.5, "latest_week": "2026-07-17", "one_week_move": -14.9, "four_week_move": -9.3, "twelve_week_move": -35.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.780552, "market_dynamics_buy_signal": false, "relative_strength": -54.943489, "fair_value_gap": -94.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.9844, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-14.9% over one week, -9.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "PR Newswire", "count": 11}, {"label": "TradingView", "count": 11}, {"label": "Market source", "count": 10}, {"label": "TradingKey", "count": 6}, {"label": "Stock Titan", "count": 4}, {"label": "Simply Wall Street", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 8}, {"label": "Deals and strategy", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-14.9% over one week, -9.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption"}], "updated_at": "2026-07-22T08:08:42.115791+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}